normal blood contains an activator of plasminogen which had hitherto escaped detection because it is labile in anticoagulated blood at room temperature (Fearnley et a!., 1952 In 1953 I found that clots made from non-fibrinolytic plasma, after being steeped in fresh plasma at low temperature and then washed, showed superficial lysis on incubation, indicating that activator present in the fresh plasma had been absorbed to the clots and thereafter had converted their contained plasminogen to plasmin with consequence lysis . This led to the concept of fibrinolysis by adsorption (Fearnley, 1961) . Brit. vied, . Bull., 20, 185.) Although the endothelium of veins is rich in plasminogen activator (Todd, 1959) and indeed may be the principal source of the activator content of circulating blood Fig. 1 an occlusive thrombus halts adsorption of activator.
Before discussing fibrinolysis in occlusive vascular disease and its enhancement with drugs given by mouth, may I briefly outline the two methods we use for measuring spontaneous fibrinolysis? The first of these, the dilute blood clot lysis-time (Fearnley et al., 1957 (Fearnley and Chakrabarti, 1964) .
There is therefore evidence of an association between defective fibrinolysis and occlusive vascular disease in the heart and lower limb. That it is causal cannot of course be assumed, but this could be put to the test by therapeutic trial if it were possible to increase fibrinolytic activity pharmacologically in patients with ischaemic conditions. During the past 10 years we have been seeking to achieve this, and we think we now have a means of doing so. As a result of experiments with insulin which has a biphasic influence on fibrinolysis (Fearnley et al., 1959) we studied the effect of the sulphonylureas tolbutamide and chlorpropamide on fibrinolytic activity.
Both drugs were found to increase fibrinolytic activity in in-patients who were studied in the fasting resting state. Fig. 2 shows reduction of the blood clot lysis-time by tolbutamide in a woman with ischaemic disease. It should be noted that there was no appreciable reduction of blood glucose, suggesting that the effect of tolbutamide on fibrinolysis was not a reflection of hypoglycaemia; and also that resistance developed to the fibrinolytic effect of this drug. Similar results were obtained with chlorpropamide but it soon became apparent that resistance to the fibrinolytic effect of the sulphonylureas develops after 3-4 weeks treatment. Nevertheless these were the first drugs found to be capable of increasing fibrinolytic activity for several weeks when given by mouth (Fearnley et al., 1960) . Since the fibrinolytic effect of the sulphonylureas appeared to be independent of hypoglycaemia, it seemed possible that phenformin, which does not reduce the blood glucose levels of normoglycaemic people, might have & fibrinolytic effect, and we tried out this drug as long ago as 1960. Further studies indicated that the effect of phenformin on fibrinolysis, unlike that of the sulphonylureas, was still present at the end of 3 months treatment (Fearnley and Chakrabarti, 1964) Before describing the results obtained, I must mention that we had found that testosterone given by injection in large dosage caused a marked increase of blood fibrinolytic activity (Fearnley and Chakrabarti, 1962) and this led us to evaluate anabolic steroids given by mouth for possible fibrinolytic effects. Positive results were obtained, but as with the sulphonylureas resistance developed within a few weeks of treatment (Fearnley and Chakrabarti, 1964 ).
Returning to the trials in two groups of 18 patients, Fig. 4 shows the mean serum cholesterol, plasma fibrinogen, dilute blood clot lysis-time and euglobulin lysis-time in the group who received atromid followed by met- formin. It can be seen that atromid gave a temporary reduction of the blood clot lysis-time, and a more sustained reduction of the euglobulin lysis-time. (Fearnley et ol., 1967) . The phenformin combination was marginally superior to the metformin combination in respect of fibrinolysis and of reduction of plasma fibrinogen; but the two combinations had opposite effects on serum cholesterol, that of phenformin being favourable and that of metformin being unfavourable.
PhenFormin 100 mg.+ Ethylaestrenol 8 mg.
Mean plasma-fibrinogen, platelet stickiness, and B.L.T. patients 1-10. Having found that phenformin plus ethyloestrenol has a favourable influence on fibrinolysis, plasma fibrinogen, and serum cholesterol, we wondered whether it might influence platelet stickiness. This combination of drugs was therefore given to 20 patients with occlusive vascular disease and was found to reduce platelet stickiness to glass by 50% or more in 15 of them ). Fig. 6 shows the mean change in platelet stickiness in 10 of the patients who responded in this respect, together with reduction of their mean blood clot lysis-time and plasma fibrinogen level. Neither drug given separately had this effect, and how these drugs reduce platelet stickiness is unknown. The effect appears to be independent of their influence on fibrinolysis and plasma fibrinogen, for in a cross-over trial in 10 patients, metformin plus ethyloestrenol to our surprise was found to increase platelet stickiness in contrast to its reduction by phenformin plus ethyloestrenol. This cross-over study also confirmed the opposite effects of metformin and phenformin on serum cholesterol. It has been possible to follow the effect of phenformin plus ethyloestrenol on platelet stickiness in 12 of our original patients for 14-24 months from the beginning of treatment, and in all the effect has been sustained .
In a study of 8 patients atromid-S (that is clofibrate without androsterone) had an effect on platelet stickiness which was not sustained, and prolonged the dilute blood clot lysis-times of 5 of them, indicating that the drug has antifibrinolytic properties. The differing effects of atromid and atromid-S on fibrinolysis we attribute to the absence of androsterone from atromid-S which behaved like an anabolic steroid in the original atromid . lifTci't of phcnformin plus ethyl<r*>trcnoI on l-'.O.l*., plsisnisitihrin?Kcn, and dilutc-blood-clot lysis-time in u woman with hemiplegia. Fig. 7 . Fig. 7 shows the effects of phenformin plus ethyloestrenol on F.D.P., plasma fibrinogen, and the dilute blood clot lysis-time, of a woman studied one month after the onset of a cerebral thrombosis. It can be seen that the earliest effect was a marked increase of fibrinolytic activity followed by a 50% reduction of the plasma fibrinogen, followed by a sharp rise of F.D.P. from less than 5 ug/ml. to reach a peak of 160 ug/ml. These findings provide the first direct evidence that enhancement of fibrinolytic activity by phenformin plus ethyloestrenol, as judged by an in vitro test, is accompanied by an increased breakdown of fibrin/fibrinogen in the body. They also confirm that the dilute blood clot lysis-time reflects the behaviour of a functioning fibrinolytic mechanism in vivo. The method of assay does not determine whether the degradation products arise from fibrin on the one hand, from fibrinogen on the other, or from both. Available evidence indicates that fibrinogenolysis is encountered only in states of pathological fibrinolytic activity, and that activity of physiological degree, with which we are here concerned, is insufficient to overcome the antiplasmin defence and is thus incapable of lysing fibrinogen as opposed to fibrin. Admittedly, phenformin plus ethyloestrenol reduces raised levels of plasma fibrinogen, but this may be due to depression of biosynthesis or to a feed-back mechanism from removal of fibrin. It seems likely therefore that the increase of F.D.P. by phenformin plus ethyloestrenol in our patients was due to lysis of fibrin (Fearnley et cil, 1969) .
If this be accepted, more than one possibility needs considering. Should this combination of drugs promote deposition of fibrin (though there is no evidence that it does) then increased fibrinolytic activity and rise of F.D.Pcould be homeostatic consequences of such an effect. Were this so, however, the expected sequence would be reduction of plasma fibrinogen followed by increased fibrinolytic activity and rise of F.D.P. Despite some overlap the general tendency in our patients has been for increased fibrinolytic activity, and usually for the increase of F.D.P., to antedate or to accompany reduction of plasma fibrinogen. We think it likely therefore that phenformin plus ethyloestrenol removes deposited fibrin by increasing fibrinolytic activity, in other words that these drugs achieve pharmacological defibrination. If this is so, the findings do not of course establish the site of fibrin removal, though vascular endothelium seems one likely place. At the same time we cannot altogether exclude the possibility that phenformin plus ethyloestrenol in some way influences the rate of fibrinogen/fibrin turnover in the body, and here studies with radioactive fibrinogen before and during treatment might be of value.
In conclusion, the possible prophylactic value of pharmacological defibrination in occlusive vascular and perhaps other disorders can be settled only by a controlled clinical trial. Finally, I must emphasize that the object of such treatment is the prevention of further occlusions, since the effects of the drugs take too long to develop to be applicable to acute situations, for which " arvin " and thrombolytic agents like streptokinase would seem to be more suitable. In a nutshell, the intention of pharmacological fibrinolysis is long-term prophylaxis in patients with occlusive vascular disease.
